62
Participants
Start Date
January 31, 2012
Primary Completion Date
February 28, 2015
Study Completion Date
February 28, 2015
Romiplostim
The starting dose of romiplostim is 1 µg/kg administered weekly by subcutaneous injection. Participants will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10\^9/L and ≤ 200 x 10\^9/L.
Placebo
Matching placebo administered by subcutaneous injection
Research Site, Randwick
Research Site, Parkville
Research Site, Herston
Research Site, New York
Research Site, New York
Research Site, Pittsburgh
Research Site, Philadelphia
Research Site, Washington D.C.
Research Site, Atlanta
Research Site, Nashville
Research Site, Louisville
Research Site, Columbus
Research Site, Cincinnati
Research Site, Indianapolis
Research Site, Detroit
Research Site, Iowa City
Research Site, La Crosse
Research Site, Chicago
Research Site, Peoria
Research Site, Kansas City
Research Site, Omaha
Research Site, New Orleans
Research Site, Fort Worth
Research Site, Houston
Research Site, Las Vegas
Research Site, San Diego
Research Site, Orange
Research Site, New Brunswick
Research Site, Hamilton
Research Site, Toronto
Research Site, Montreal
Research Site, Montreal
Research Site, Québec
Lead Sponsor
Amgen
INDUSTRY